Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tardive dyskinesia.

J Gerlach1, D E Casey

  • 1Psychiatric Department, Sct. Hans Hospital, Roskilde, Danmark.

Acta Psychiatrica Scandinavica
|April 1, 1988
PubMed
Summary
This summary is machine-generated.

Tardive dyskinesia (TD), affecting 15% of patients on neuroleptic drugs, involves involuntary movements. Prevention and gradual dose reduction are key, with some evidence suggesting moderate doses may be safely continued long-term.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

THE MIDLATITUDE CONTINENTAL CONVECTIVE CLOUDS EXPERIMENT (MC3E).

Bulletin of the American Meteorological Society·2020
Same author

Improved method for MR microscopy of brain tissue cultured with the interface method combined with Lenz lenses.

Magnetic resonance imaging·2018
Same author

Hypersensitivity pneumonitis and antigen identification--An alternate approach.

Respiratory medicine·2016
Same author

Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.

International journal of clinical practice·2014
Same author

Principles of practice from the European expert panel on the contemporary treatment of schizophrenia.

International journal of psychiatry in clinical practice·2014
Same author

Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity.

Journal of psychopharmacology (Oxford, England)·2012
Same journal

AI-Associated Psychotic Phenomena: Collect Before You Classify.

Acta psychiatrica Scandinavica·2026
Same journal

Developmental Trauma as a Prognostic Factor for Later Psychotic Disorder in an Adolescent Clinical Cohort: A 20-Year Follow Up Study.

Acta psychiatrica Scandinavica·2026
Same journal

The Prevalence of Obstructive Sleep Apnoea in Schizophrenia, Bipolar Disorder and Major Depressive Disorder: A Systematic Review With Meta-Analysis.

Acta psychiatrica Scandinavica·2026
Same journal

Use of Glucagon-Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009-2024.

Acta psychiatrica Scandinavica·2026
Same journal

Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5-Year Follow-Up.

Acta psychiatrica Scandinavica·2026
Same journal

Leveraging Family Genetic Risk Scores to Understand the Etiology of Suicidal Behaviors and Their Associations With Psychiatric Disorders.

Acta psychiatrica Scandinavica·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Movement Disorders

Background:

  • Tardive dyskinesia (TD) is a neurological disorder characterized by involuntary movements, affecting approximately 15% of individuals undergoing neuroleptic drug treatment.
  • Neuroleptic, or antidopaminergic, drugs are recognized as the primary cause of TD, with dosage and treatment duration potentially influencing its development.

Purpose of the Study:

  • To review the prevalence, etiology, pathophysiology, prevention, and treatment of tardive dyskinesia.
  • To explore current understanding and evolving hypotheses regarding the mechanisms underlying TD.
  • To provide guidance on managing neuroleptic medication in relation to TD risk.

Main Methods:

  • Literature review and synthesis of existing research on tardive dyskinesia.

Related Experiment Videos

  • Analysis of epidemiological data on TD prevalence.
  • Examination of proposed pathophysiological mechanisms and clinical management strategies.

    • Main Results:

    • Neuroleptic drugs are the main cause of TD, with prevalence around 15%.
    • The exact pathophysiology remains unclear, with evolving theories beyond simple dopamine hypersensitivity.
    • Atypical neuroleptics like clozapine may carry a lower risk of TD.
    • Prevention strategies include minimizing antidopaminergic effects, while treatment often involves gradual dose reduction.

    Conclusions:

    • Minimizing antidopaminergic exposure is crucial for TD prevention.
    • While gradual dose reduction is a primary treatment, recent findings suggest moderate doses may be safely continued long-term without progression.
    • Further research into TD pathophysiology is needed to refine treatment and prevention.